Concepts (59)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Skin | 4 | 2024 | 377 | 0.970 |
Why?
|
| Lupus Erythematosus, Cutaneous | 2 | 2021 | 13 | 0.870 |
Why?
|
| Hypersensitivity | 1 | 2022 | 61 | 0.740 |
Why?
|
| Lupus Erythematosus, Discoid | 1 | 2021 | 8 | 0.730 |
Why?
|
| Lupus Nephritis | 1 | 2021 | 34 | 0.710 |
Why?
|
| Wearable Electronic Devices | 1 | 2022 | 68 | 0.710 |
Why?
|
| Gene Expression Profiling | 2 | 2024 | 761 | 0.600 |
Why?
|
| Dermatitis, Allergic Contact | 2 | 2024 | 13 | 0.430 |
Why?
|
| Dermatitis, Irritant | 1 | 2024 | 4 | 0.230 |
Why?
|
| Hypersensitivity, Delayed | 1 | 2024 | 19 | 0.230 |
Why?
|
| Gene Ontology | 1 | 2021 | 38 | 0.180 |
Why?
|
| Nickel | 1 | 2022 | 66 | 0.180 |
Why?
|
| Chemokines | 1 | 2021 | 95 | 0.170 |
Why?
|
| Fas Ligand Protein | 1 | 2018 | 41 | 0.150 |
Why?
|
| Toll-Like Receptor 7 | 1 | 2018 | 102 | 0.140 |
Why?
|
| Simvastatin | 1 | 2017 | 27 | 0.130 |
Why?
|
| Toll-Like Receptor 9 | 1 | 2018 | 211 | 0.130 |
Why?
|
| Membrane Glycoproteins | 1 | 2018 | 669 | 0.120 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2017 | 217 | 0.110 |
Why?
|
| Vitiligo | 1 | 2017 | 126 | 0.110 |
Why?
|
| Humans | 7 | 2024 | 62682 | 0.090 |
Why?
|
| Stevens-Johnson Syndrome | 1 | 2024 | 8 | 0.060 |
Why?
|
| Drug Eruptions | 1 | 2024 | 15 | 0.060 |
Why?
|
| Interleukin-4 | 1 | 2024 | 141 | 0.060 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2024 | 174 | 0.050 |
Why?
|
| Single-Cell Analysis | 1 | 2024 | 109 | 0.050 |
Why?
|
| Sequence Analysis, RNA | 1 | 2024 | 171 | 0.050 |
Why?
|
| Surgical Tape | 1 | 2022 | 1 | 0.050 |
Why?
|
| Proteomics | 1 | 2024 | 284 | 0.050 |
Why?
|
| Interferon-gamma | 1 | 2024 | 567 | 0.050 |
Why?
|
| Allergens | 1 | 2022 | 52 | 0.050 |
Why?
|
| China | 1 | 2022 | 169 | 0.050 |
Why?
|
| Diagnosis, Differential | 1 | 2024 | 964 | 0.050 |
Why?
|
| Transcriptome | 1 | 2024 | 380 | 0.040 |
Why?
|
| Adult | 3 | 2024 | 16629 | 0.040 |
Why?
|
| Middle Aged | 3 | 2024 | 17365 | 0.040 |
Why?
|
| Male | 4 | 2024 | 29487 | 0.040 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2024 | 671 | 0.040 |
Why?
|
| Biomarkers | 1 | 2024 | 1385 | 0.040 |
Why?
|
| Ovalbumin | 1 | 2018 | 116 | 0.040 |
Why?
|
| Mice | 2 | 2024 | 10804 | 0.040 |
Why?
|
| Th1 Cells | 1 | 2018 | 175 | 0.030 |
Why?
|
| Autoantibodies | 1 | 2018 | 182 | 0.030 |
Why?
|
| Body Surface Area | 1 | 2017 | 11 | 0.030 |
Why?
|
| Chemokine CXCL10 | 1 | 2017 | 58 | 0.030 |
Why?
|
| Female | 3 | 2024 | 32495 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 1 | 2018 | 893 | 0.030 |
Why?
|
| Interferon Type I | 1 | 2018 | 186 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2017 | 366 | 0.030 |
Why?
|
| Lymphocyte Activation | 1 | 2018 | 759 | 0.030 |
Why?
|
| B-Lymphocytes | 1 | 2018 | 569 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2017 | 739 | 0.030 |
Why?
|
| Animals | 2 | 2024 | 20584 | 0.030 |
Why?
|
| Mice, Knockout | 1 | 2018 | 2099 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2017 | 1541 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2018 | 2174 | 0.020 |
Why?
|
| Young Adult | 1 | 2017 | 4633 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2017 | 5591 | 0.020 |
Why?
|
| Adolescent | 1 | 2017 | 6172 | 0.020 |
Why?
|